Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck.
Animals
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Cell Line, Tumor
Cisplatin
/ pharmacology
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Neoplasm Proteins
/ metabolism
Peptide Fragments
/ chemistry
Proto-Oncogene Proteins
/ chemistry
Squamous Cell Carcinoma of Head and Neck
/ drug therapy
Treatment Outcome
Xenograft Model Antitumor Assays
Zebrafish
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
04 12 2019
04 12 2019
Historique:
received:
31
07
2019
accepted:
31
10
2019
revised:
16
10
2019
entrez:
6
12
2019
pubmed:
6
12
2019
medline:
1
9
2020
Statut:
epublish
Résumé
Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common cancer worldwide, with overall survival of less than 50%. Current therapeutic strategies involving a combination of surgery, radiation, and/or chemotherapy are associated with debilitating side effects, highlighting the need for more specific and efficacious therapies. Inhibitors of BCL-2 family proteins (BH3 mimetics) are under investigation or in clinical practice for several hematological malignancies and show promise in solid tumors. In order to explore the therapeutic potential of BH3 mimetics in the treatment of SCCHN, we assessed the expression levels of BCL-2, BCL-X
Identifiants
pubmed: 31801952
doi: 10.1038/s41419-019-2150-8
pii: 10.1038/s41419-019-2150-8
pmc: PMC6892862
doi:
Substances chimiques
Antineoplastic Agents
0
Bax protein (53-86)
0
Neoplasm Proteins
0
Peptide Fragments
0
Proto-Oncogene Proteins
0
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
912Références
Laryngoscope. 2002 Apr;112(4):638-44
pubmed: 12150516
J Pathol. 2009 Feb;217(3):398-407
pubmed: 19009587
Front Cell Neurosci. 2015 Aug 31;9:321
pubmed: 26379496
Int J Mol Sci. 2017 Nov 15;18(11):
pubmed: 29140271
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
J Oral Maxillofac Pathol. 2018 Sep-Dec;22(3):325-331
pubmed: 30651675
Br J Cancer. 2016 Mar 15;114(6):638-41
pubmed: 26954718
MAbs. 2016;8(1):27-36
pubmed: 26418356
Sci Transl Med. 2015 Mar 18;7(279):279ra40
pubmed: 25787766
Nat Cell Biol. 2012 Apr 29;14(6):575-83
pubmed: 22544066
Cell Rep. 2014 Aug 7;8(3):688-95
pubmed: 25066122
Oncol Res. 2005;15(5):249-55
pubmed: 16261844
Nature. 2005 Jun 2;435(7042):677-81
pubmed: 15902208
N Engl J Med. 2016 Jan 28;374(4):311-22
pubmed: 26639348
Leukemia. 2016 Jun;30(6):1273-81
pubmed: 26987906
Nature. 2016 Oct 27;538(7626):477-482
pubmed: 27760111
Cell Death Dis. 2019 Jul 15;10(8):540
pubmed: 31308358
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Nat Med. 2013 Feb;19(2):202-8
pubmed: 23291630
Immunol Res. 2015 Jun;62(2):225-33
pubmed: 25929430
Lancet Oncol. 2018 Feb;19(2):216-228
pubmed: 29339097
Oncotarget. 2019 Jan 11;10(4):494-510
pubmed: 30728900
Oncotarget. 2016 Mar 29;7(13):16731-44
pubmed: 26934442
Arch Otolaryngol Head Neck Surg. 1999 Apr;125(4):417-22
pubmed: 10208679
Mol Cancer Ther. 2016 Sep;15(9):2011-7
pubmed: 27535975
Tumour Biol. 2006;27(4):195-200
pubmed: 16675913
Leukemia. 2019 Jan;33(1):262-266
pubmed: 30008477
Cancer. 1999 Jan 1;85(1):164-70
pubmed: 9921989
Cancer Cell Int. 2019 Jan 14;19:16
pubmed: 30651721
J Cell Sci. 2018 May 15;131(10):
pubmed: 29764917
Ann Otol Rhinol Laryngol. 1997 Jun;106(6):445-50
pubmed: 9199601
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
J Clin Oncol. 2011 Mar 1;29(7):909-16
pubmed: 21282543
Int J Clin Exp Pathol. 2014 Oct 15;7(11):7360-77
pubmed: 25550772
Cancer Res. 2008 May 1;68(9):3421-8
pubmed: 18451170
Recent Pat Anticancer Drug Discov. 2011 Jan;6(1):45-57
pubmed: 21110823
Oncogene. 2018 Aug;37(32):4475-4488
pubmed: 29743589
Cell Death Differ. 2019 Jun;26(6):1037-1047
pubmed: 30185825
Anticancer Res. 1996 Jul-Aug;16(4C):2403-8
pubmed: 8816842
Eur J Surg Oncol. 2002 Sep;28(6):667-72
pubmed: 12359206
Nat Rev Mol Cell Biol. 2008 Jan;9(1):47-59
pubmed: 18097445
Cancer Discov. 2018 Dec;8(12):1582-1597
pubmed: 30254093
Nat Commun. 2016 Jan 20;7:10384
pubmed: 26785948
PLoS One. 2014 Nov 19;9(11):e111927
pubmed: 25409302
Mol Cancer Ther. 2017 Oct;16(10):2178-2190
pubmed: 28611106
Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):435-41
pubmed: 11173138
Cancer Manag Res. 2017 Aug 18;9:363-371
pubmed: 28860859
Cell. 2007 Mar 23;128(6):1173-86
pubmed: 17382885
Nat Commun. 2018 Dec 17;9(1):5341
pubmed: 30559424
J Laryngol Otol. 2016 May;130(S2):S9-S12
pubmed: 27841107
Mol Pharmacol. 2009 May;75(5):1231-9
pubmed: 19246337